🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07627022
Starting soon Not applicable

Impact of a Reminder App on Physical Activity During Radiation Therapy for Lung Cancer

NCT07627022 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2026-07-01
Last updated
2026-06-04

Condition(s) studied

Lung Cancer

Investigational drug(s) / intervention(s)

mobile application (reminder app)Standard radiotherapy

mobile application (reminder app): Mobile application (reminder app) that reminds patients three to four times daily to walk a pre-defined number of steps.

Standard radiotherapy: Patients receive standard radiotherapy or radio-chemotherapy for lung cancer.

Study summary

The primary objective of this prospective randomized trial is to explore whether the use of a smart phone-based reminder application is associated with a change in physical activity during radiation therapy in patients with lung cancer. The primary endpoint focuses on the within-patient change in physical activity between Week 1 and Week 5, with comparison between treatment groups to assess potential differences attributable to the intervention.

Secondary objectives include the exploratory assessment of patient satisfaction with the reminder app, its impact on the use and perception of digital health technology.

A total of 28 evaluable patients in the Full Analysis Set (approximately 14 per treatment arm) are required to detect a clinically relevant difference corresponding to a probability of superiority of approximately 0.65 with 80% power at a two-sided significance level of 0.05. Assuming that approximately 10% of patients will not be evaluable for the primary endpoint, a total of 32 patients will be randomized.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Histologically proven lung cancer 2. Treatment with ≥50 Gy of conventionally fractionated radiation therapy 3. Possession of and ability to use a smart phone plus a step counter 4. Age ≥18 years 5. Written informed consent 6. Capacity of the patient to consent Exclusion Criteria: 1\. Expected non-compliance

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Department of Oncology Vejle Hospital, University Hospital of Southern Denmark Vejle Denmark
Radiation Oncology Department, Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic Tbilisi Georgia
MVZ RON Niedersachsen Strahlentherapie GmbH Hanover Lower Saxony
Department of Radiation Oncology, Christian-Albrechts University Kiel Schleswig-Holstein
Department of Pulmonology, University of Luebeck Lübeck Schleswig-Holstein
Department of Radiation Oncology, University of Luebeck Lübeck Schleswig-Holstein
Department of Radiotherapy, Institute of Oncology Ljubljana and Faculty of Medicine, University of Ljubljana Ljubljana Slovenia

More University Hospital Schleswig-Holstein trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07627022 on ClinicalTrials.gov ↗ ← All trials in Germany